{"id":"W2269708877","doi":"10.1200/jco.2006.24.18_suppl.13540","title":"A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (MCRC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"","keywords":"Medicine; Capecitabine; Irinotecan; Neutropenia; Nausea; Oxaliplatin; Internal medicine; Adverse effect; Toxicity; Colorectal cancer; Vomiting; Phases of clinical research; Gastroenterology; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002425206,0.00204994,0.002590013,0.0005821888,0.0005472889,0.001016197,0.001161179,0.001267725,0.003216477],"category_scores_gemma":[0.001574597,0.001067999,0.001439968,0.0007530295,0.001825965,0.001076775,0.0004504152,0.003466041,0.0007094766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001072184,"about_ca_system_score_gemma":0.002571569,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001463016,"about_ca_topic_score_gemma":0.00274224,"domain_scores_codex":[0.9992742,0.0003650677,0.00004100848,0.0001210619,0.00006294785,0.0001358472],"domain_scores_gemma":[0.9986394,0.0002144287,0.0002014448,0.0001038811,0.0000598167,0.0007810832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7517102,0.1574134,0.005157722,0.0007724183,0.0007638526,0.000376814,0.000477885,0.001747671,0.04009274,0.0001982357,0.001760879,0.03952815],"study_design_scores_gemma":[0.4814123,0.5077088,0.006207383,0.00001757471,0.0003268253,0.0001709102,0.00004863774,0.0006450952,0.002099952,0.0001034835,0.001235158,0.00002393973],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939026,0.0009983239,0.0004695906,0.0002869639,0.0001065459,0.002806737,0.0005162337,0.00004365064,0.0008695608],"genre_scores_gemma":[0.9851266,0.002305205,0.002763434,0.0008587751,0.0003197195,0.003744989,0.001865589,0.00003186479,0.002983993],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003216477,"threshold_uncertainty_score":0.01282591,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07546783028022801,"score_gpt":0.4533167482677306,"score_spread":0.3778489179875025,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}